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1997 with at least one ICD-9 code of ischemic heart
disease or heart failure in 1996 were included. From this
cohort all patients with AF (ICD-9 427.31) were identi-
ﬁed and two non-AF controls were randomly selected for
each case. Resource use and charges were compared using
univariate tests. Logistic and log-linear regression tech-
niques were also used for risk-adjustment.
RESULTS: 3.3% of AF-patients (n = 831) and 2.5% of
non-AF patients (n = 1662) had a cerebrovascular event
in 1997. One-year median resource use in the AF and
non-AF group was as follows: hospital days: 7.0 vs. 6.0;
outpatient visits: 8.0 vs. 6.0; home health visits: 6.0 vs.
5.0; ER visits: 1.0 vs. 1.0, nursing home days: 7.5 vs. 6.0.
The median annual total charges per AF patient and non-
AF patient were $22,213 and $17,472, respectively. On
controlling for age, gender, Charlson Comorbidity Index,
type of CVD, and prior year’s hospital use, the two
groups only differed signiﬁcantly in number of outpatient
visits. No differences in costs existed.
CONCLUSIONS: AF patient had a higher utilization of
outpatient visits as compared to non-AF patients. It is
possible that presence of severe underlying CVD in both
groups overwhelms the differences in the costs attribut-
able only to AF. Further examination of the pharmacy
data will help reveal any differences in drug utilization
and costs due to AF.
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OBJECTIVES: Given the high hospitalization rate asso-
ciated with congestive heart failure (CHF), the objective
of this analysis is to assess hospital resource utilization of
CHF patients treated with inotropic agents, diuretics or
both. 
METHODS: Patients hospitalized with a primary dis-
charge CHF diagnosis between July 2000 and June 2001
were identiﬁed from a hospital-based, service-level 
database of 217 health care facilities. Patients managed
with diuretic and/or inotropic drugs were segmented into
the following treatment groups: inotropics only, diuretics
only (IV, oral or both), and inotropics with diuretics (IV,
oral or both). Drug treatment, hospital unit care patterns,
and incurred mean total hospital and drug costs were
determined for each treatment group.
RESULTS: From the patient sample (N = 58,131), 53%
were treated with IV and oral diuretic therapy, 20% with
IV-only diuretics, and 14% with inotropics plus IV and
oral diuretics. Length of stay (LOS) ranged from 4 to 9
days, with intensive care unit (ICU) or subacute stepdown
unit LOS accounting for 3–6 days and inotropic-treated
cases having longer stays. Inotropic therapy was usually
initiated during the ﬁrst or second day of hospitalization.
One-third of patients treated with inotropic drugs were
transferred to the ICU during the ﬁrst hospital day while
one-third of diuretic treated cases received stepdown care.
Patients who received inotropic therapy with oral and IV
diuretics had the highest total hospital and drug costs 
at $12,461 and $382, respectively. Patients in the oral
diuretic-only treatment group had the lowest total costs
($4,380). Most patients were discharged home but more
inotropic patients expired in-hospital (4–15%) while
more diuretic cases were transferred to a skilled nursing
facility (10–12%).
CONCLUSIONS: CHF cases treated with inotropic drugs
had longer overall and ICU LOS, higher hospital costs
and in-hospital mortality when compared to diuretic-only
treated patients.
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OBJECTIVE: Clinical trials have demonstrated the safety
and efﬁcacy of prophylaxis with unfractionated heparin
(UFH) and low-molecular weight heparins such as enoxa-
parin against venous thromboembolism in acutely-ill
medical inpatients. The objective of this study was to esti-
mate the cost-effectiveness of these alternative methods of
thromboprophylaxis in this population. 
METHODS: We used techniques of decision analysis 
and data from secondary sources to estimate the cost-
effectiveness of thromboprophylaxis in acutely-ill medical
inpatients. A hypothetical cohort of 10,000 patients was
assumed to receive, alternatively, prophylaxis with: (1)
enoxaparin 40mg qd; (2) UFH 5,000IU bid; (3) UFH
5,000IU tid; or (4) no prophylaxis. For each strategy, 
we estimated the 30-day risks of thromboembolism
(deep-vein thrombosis and/or pulmonary embolism),
complications of prophylaxis and therapy (heparin-
induced thrombocytopenia and bleeding), mortality, and
costs of prophylaxis, diagnostic testing and treatment.
Cost per death averted was assessed for each method of
prophylaxis relative to no prophylaxis. A background
mortality risk of 10% was assumed.
RESULTS: In a cohort of 10,000 inpatients, expected
numbers of deaths over 30 days were 1,041 for enoxa-
parin, 1,058 for UFH bid, 1,058 for UFH tid, and 1,089
for no prophylaxis. Corresponding estimates of the
expected costs of prevention, diagnosis, and manage-
ment of venous thromboembolism were $3,655,800,
$3,750,400, $4,300,400, and $3,363,000 (2001 US$).
Relative to no prophylaxis, the cost per death averted 
was $6,101 for enoxaparin, $12,498 for UFH bid, and
$30,240 for UFH tid. Incremental analyses indicated that
prophylaxis with enoxaparin is both more effective and
